CAMBRIDGE ENTERPRISE Ltd and Sphere Fluidics | Date: 2011-08-17
This invention relates to methods and systems for providing chemical and/or biological materials. Thus we describe a method of providing a chemical or biological material in a quantised form, the method comprising: preparing an emulsion comprising a plurality of microdroplets each holding a controlled amount of said material; storing said chemical or biological material in said microdroplets in said emulsion; transferring a portion of said emulsion microdroplets to a container for transportation; transporting said container to a user of said material, wherein said user receives said material in a quantised form in said microdroplets of said emulsion; and de-emulsifying said received microdroplets containing said material in quantised form to extract said material for subsequent use.
Sphere Fluidics | Date: 2014-07-30
We describe a method of label-free cell and/or particle sorting in a microfluidic device, the method comprising; providing a stream of aqueous droplets in oil in a channel of said microfluidic device, wherein at least some of said droplets include cells and/or particles illuminating said stream from a first direction; detecting, for example, scattered light from cells and/or particles within said aqueous droplets in a second direction; determining, for example, a number of said cells and/or particles in each droplet from the scattered light; and sorting said aqueous droplets into one of a plurality of differentiated streams responsive to said determined number. The method further comprises modifying a refractive index of said oil to more closely match a refractive index of said aqueous droplets to reduce light scattered from boundaries of said droplets. Optionally a volume of the droplets is also controlled. In embodiments the oil is fluorous oil. We describe examples of preferred refractive index modifying compounds.
Agency: GTR | Branch: Innovate UK | Program: | Phase: Collaborative Research & Development | Award Amount: 1.08M | Year: 2015
Cell therapy promises to become a globally used approach to treat important diseases, such as cancer. Current regimes can involve removing a patients white blood cells (e.g. T-cells), reprogramming them to fight cancer and then reintroducing them to the patient. Current cellular reprogramming techniques are very inefficient (e.g. as low as 3%) and involve complex, inflexible techniques for production. Our proposed project synergises cellular reprogramming and manufacturing expertise (from Cell Therapy Catapult) with novel, single cell manipulation and microfluidic expertise (from Sphere Fluidics Limited) with cell therapy manufacturing and end user expertise (from Cellular Therapeutics Ltd and GlaxoSmithKline). This world-class team will build, test and demonstrate a new cell therapy production microfluidic device that enables the flexible manufacture of high quality, engineered cells in a more rapid, efficient and less costly manner. This will accelerate discovery and improve production of new, valuable cell therapies - giving UK companies a significant lead in this area and improving the quality of patient healthcare across the world.
Sphere Fluidics | Date: 2014-07-30
The present invention provides an emulsion for sorting droplets in a microfluidic device, the emulsion comprising:
Sphere Fluidics | Date: 2016-05-27
Biochips; Bio-chips for research or scientific purposes; Biochips for use in single cell analysis;systems for therapeutic discovery; Biochips for use with laboratory apparatus and instruments for use in biopharmaceutical discovery and development; Biochips for use with laboratory apparatus and instruments for antibody discovery and assay isolation of cell lines.
Sphere Fluidics | Date: 2014-06-23
Laboratory apparatus and instruments for use in biopharmaceutical discovery and development, namely, laboratory apparatus and instruments for antibody discovery and assay isolation of cell lines expressing high levels of antibodies; Laboratory apparatus and instruments for use in biopharmaceutical discovery and development, namely, machines comprising or containing microfluidic pumps, biochips, optics and plate moving parts that aspirates, assays, sorts and dispenses single cells; Component parts and fittings for the foregoing laboratory apparatus and instruments.
Sphere Fluidics | Date: 2016-11-25
chemical reagents used for non-medical purposes; surfactants; biocompatible surfactants; biocompatible surfactants for use in stabilising pico-droplets used for single cell analysis.
Agency: GTR | Branch: Innovate UK | Program: | Phase: Collaborative Research & Development | Award Amount: 139.55K | Year: 2014
Synthetic biology has advanced genetic manipulation by applying engineering principles (Design-Build-Test) to enable new discoveries by modifying safe microbes with custom DNA. The ability to write DNA has accelerated, but synthetic biology is now limited by a lack of high-throughput measurement methods to assess performance of custom-built strains. The proposed project links foundational synthetic biology expertise at Imperial College London with microfluidics and mass spectrometry (MS) expertise at Sphere Fluidics Limited. This synergistic team will build, test and demonstrate a new microfluidics-MS platform that enables in-depth analysis of the performance of hundreds of thousands of engineered microbes per day (conventional techniques use high sample volumes and can only test around 10,000 samples a day). To date, most synthetic biologists have only been able to analyse one gene at a time. Uniquely, our MS approach will enable analysis of multiple genes and components of artificial pathways. This will accelerate the discovery, and improve production of new, valuable medicines and fuel sources, and generate valuable, nascent Tools and Services for commercialisation.
Agency: GTR | Branch: Innovate UK | Program: | Phase: Collaborative Research & Development | Award Amount: 234.41K | Year: 2014
Sphere Fluidics Limited is an SME focusing on the development of novel, single cell analysis technologies. MedImmune, the global biopharmaceuticals arm of AstraZeneca, is a pioneer in biopharmaceutical discovery and development. Both companies have pooled their synergistic, science skills to propose the development of a unique, integrated microfluidic instrument that uses miniaturisation and novel chips to process pools of cells and rapidly isolate single cells for applications in biopharmaceutical research and development.